Tue Aug 20 2019
ViroGates has completed the development and regulatory approval of its first suPARnostic® TurbiLatex product, based on the turbidimetric technology.
The suPARnostic® TurbiLatex product has initially been developed and approved for the Roche Diagnostics cobas C 111 analyzer. Roche Diagnostics is the market leader in the clinical chemistry area in the hospital markets in Europe and offers integrated diagnostic solutions on its cobas platforms.
The launch of the cobas C 111 application is the first step in providing products for the Roche Diagnostics platform.
Next step is to validate the suPARnostic® TurbiLatex on the higher throughput instruments such as the cobas c 500 and c 700 series that are most commonly used in diagnostic laboratories.
The suPARnostic® Turbilatex product enables automatic handling of blood samples at central laboratories, and allows the medical professionals to obtain results in exactly the same manner that most other blood parameters are reported.
This means, that doctors will be able to obtain suPAR measurements at the same time as they receive most other diagnostic data thereby facilitating efficient decision making.
The TurbiLatex product is based on a technology called turbidimetry that measures the loss of intensity of transmitted light due to the scattering effect of particles suspended in the blood sample. The principle of measuring blood samples by using turbidimetry is very important in relation to immunoassays, as it is the basis for almost all central laboratory clinical chemistry instrument platforms in hospitals.